Recent developments include intellectual property portfolio updates, expanded licensing agreements, new patent grants, and Nasdaq uplisting activities.

• Caring Brands provided an intellectual property portfolio update in August 2026 [N1].
• The company and SanPellegrino Cosmetics Private Limited announced an expanded multi-territory licensing agreement for Photocil and Hair Enzyme Booster in June 2026 [N2].
• Caring Brands secured two new U.S. patents strengthening Hair Enzyme Booster technology in February 2026 [N3].
• The company announced an exclusive global license to manufacture and market Emesyl in January 2026 [N4].
• Caring Brands closed a $4,000,000 million uplisting to Nasdaq in November 2025 [N5].
• The company announced pricing of the $4,000,000 million uplisting to Nasdaq in November 2025 [N6].

Caring Brands has developed a diversified product pipeline with clinical validation and patent protection, including products addressing significant health conditions such as psoriasis, vitiligo, and hair loss. The company has secured licensing agreements expanding its geographic reach, including multi-territory licenses and partnerships with established cosmetic companies. Recent patent grants and intellectual property updates strengthen its technological position. The company maintains a strong liquidity position relative to its current liabilities, supporting ongoing operations and product development. These factors provide a foundation for potential growth in niche wellness markets.

The company has nominal revenues and ongoing net losses, indicating limited current commercial traction. It faces significant risks related to Nasdaq listing compliance, with a recent Staff Delisting Determination and an uncertain appeal outcome. Market adoption of its products, particularly in the US, has been challenged by lack of dedicated sales and marketing teams, leading to product removals. The wellness consumer products sector is competitive, and regulatory and market acceptance risks remain. The company's ability to secure additional financing and sustain operations is uncertain, which may impact its business continuity and growth prospects.

Caring Brands' moat is primarily based on its portfolio of issued and pending patents protecting its proprietary wellness products, including the Hair Enzyme Booster technology with multiple patents. The company also leverages licensing agreements with established partners for manufacturing and marketing in multiple territories, which may provide market access advantages. Its focus on clinical validation and compliance with regulatory standards for OTC and cosmetic products supports product credibility. However, the company operates in competitive wellness and dermatology markets with established players, and its commercial scale and sales infrastructure are currently limited, which constrains its competitive moat.

• Nasdaq Listing Compliance Risk: The company is not in compliance with Nasdaq's continued listing requirements, received a Staff Delisting Determination in July 2026, and faces potential suspension and delisting pending a hearing outcome. Failure to regain compliance could materially affect stock liquidity, market price, and capital raising ability [S2].
• Market Adoption and Commercialization Risk: Products such as Photocil were removed from the US market due to insufficient sales and lack of dedicated sales and marketing teams. Future market penetration depends on effective commercialization strategies, regulatory approvals, and competitive dynamics [S1].
• Financial Risk: The company reports nominal revenues and ongoing net losses, with reliance on financing and licensing agreements. Continued losses may reduce stockholders' equity and impact operational sustainability [S2].
• Regulatory and Competitive Risk: Products are subject to regulatory requirements for OTC and cosmetic products, including FDA registration and compliance with USP monographs. Competition in wellness and dermatology markets may limit market share and growth [S1].

• Caring Brands, Inc. is a wellness consumer products company offering over-the-counter (OTC) and cosmetic consumer products.
• The product pipeline includes hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products.
• The company ensures product mechanism of action is established, efficacy is determined through controlled clinical trials, products are protected by issued and filed patents, and products have acceptable commercial stability [S1].
• Photocil is a narrow band UV filter product for vitiligo and psoriasis treatment, launched commercially in India in Q3 2022 and briefly in the US from Dec 2022 to Feb 2023 before removal due to insufficient sales and lack of dedicated sales and marketing team; a US relaunch is planned for 2026 [S1].
• Photocil is marketed as an OTC cosmetic product in India and was FDA-registered in the US with labeling but does not require FDA pre-market approval as it uses Generally Recognized as Safe and Effective (GRASE) ingredients [S1].
• Hair Enzyme Booster (JW-700) is a cosmetic product designed to enhance minoxidil efficacy by increasing sulfotransferase enzymes; it is marketed in India and the US, launched on Amazon in October 2024 [S1].
• Hair Enzyme Booster has 2 granted and 5 pending patents and is licensed to Taisho in Japan with milestone payments and royalties [S1].
• CB-101 is an OTC topical treatment for atopic dermatitis (eczema) undergoing reformulation, planned for US online availability in 2Q 2026 under a USP monograph [S1].
• NoStingz is a planned reformulated sunscreen product designed to protect against UV rays and jellyfish stings, intended to comply with FDA sunscreen guidelines [S1].
• Manufacturing is conducted by Stella Industries Ltd in India and DCR Labs in Florida, both compliant with FDA Current Good Manufacturing Practice (CGMP) regulations [S1].
• The company had nominal revenues of $4,215 as of December 31, 2025, and a net loss of $638,726 for the quarter ended June 30, 2026 [S2].
• As of June 30, 2026, the company had cash and equivalents of $1,820,365, current assets of $1,909,623, current liabilities of $384,646, a current ratio of 4.96, and a cash ratio of 4.73 [S2].
• The company is not in compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5 million in stockholders' equity and received a Staff Delisting Determination on July 15, 2026, with a hearing scheduled for August 25, 2026 [S2].
• The company submitted a plan to regain compliance involving amending the Certificate of Designation of its Series A Convertible Redeemable Preferred Stock and obtaining additional financing, but the Staff denied the request due to lack of a definitive agreement [S2].
• The company closed a $4 million uplisting to Nasdaq in November 2025 [N5][N6].
• Caring Brands announced an exclusive global license to manufacture and market Emesyl in January 2026 [N4].
• The company secured two new U.S. patents strengthening Hair Enzyme Booster technology in February 2026 [N3].
• Caring Brands and SanPellegrino Cosmetics Private Limited announced an expanded multi-territory licensing agreement for Photocil and Hair Enzyme Booster in June 2026 [N2].
• The company provided an intellectual property portfolio update in August 2026 [N1].